Novo Nordisk

Acknowledging the intensifying competition

06/06/25 -"While a more cautious approach to our estimates has resulted in c.11% reduction in the target price, we still see Novo as a good investment opportunity at the current share price levels. After a ..."

PDF page sample
Pages
74
Language
English
Published on
06/06/25
Download
You may also be interested by these reports :
06/06/25
While a more cautious approach to our estimates has resulted in c.11% reduction in the target price, we still see Novo as a good investment ...
06/06/25
After incorporating our 2027 projections with double-digit top-line growth due to the upcoming product launches, we have reduced our long-term sales ...
02/06/25
We have updated our estimates with the latest figures. The EPS has improved due to lower-than-expected R&D costs. This improvement is supported by ...
01/06/25
CureVac has repositioned itself as an early-stage biotech company following the out-licensing of its infectious disease portfolio to GSK. The deal ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO